The Cosmetic, Toiletry and Fragrance Association, Inc.

1133 15th STREET, N.W., WASHINGTON, D.C. 20005 • 202/331-1770 • TELEX 89-2673

James H. Merritt
President

Norman F. Estrin, Ph.D.
Vice President– Science

M I N U T E S

CTFA TALC TASK FORCE

A meeting of the CTFA Talc Task Force was held on March 11th, 1976 at the CTFA offices in Washington, D.C. Those in attendance were:

George Sandland, Bristol-Myers Company (Chairman)
John E. Clements, Pfizer, Inc.
Ray Krammer, Whittaker, Clark & Daniels
George Lee, Johnson & Johnson Baby Products Company
Monroe Messinger, Chesebrough-Pond's Inc.
Roderick A. Mundy, Sterling Drug Inc.
Louis D. Murino, Cyprus Industrial Minerals Company
D.R. Petterson, Johnson & Johnson Baby Products Company
Fred Roesch, Whittaker, Clark & Daniels
Robert Rolle, Johnson & Johnson Baby Products Company
John P. Schelz, Johnson & Johnson Baby Products Company
Maurice Siegel, Faberge, Inc.
J.C. Simko, Jr., Colgate-Palmolive Company
Harold Stanley, Pfizer, Inc.
Ian Stewart, Walter C. McCrone Associates
Robert Suffis, The Mennen Company
S. Thompson, R.T. Vanderbilt & Company
John J. Travers, Avon Products, Inc.
William C. Waggoner, Johnson & Johnson Baby Products Company
Norman F. Estrin, CTFA

Mr. Sandland opened the meeting and proceeded with the agenda.

1. Status Review

   A. Talc Standards and Methods

      Copies of the proposed specification and methods, plus copies of a letter to Dr. Schaffner were distributed to task force members.

   B. A status report (dated March 8th, 1976), prepared by Dr. Petterson, on cosmetic talc status was distributed to those present. A copy of an article by

CONTINUED ON NEXT PAGE

PLAINTIFF'S EXHIBIT
WCD-41

Dr. Rohl and Dr. Arthur M. Langer on "Identification and Quantitation of Asbestos in Talc" was distributed as it appears in Environmental Health Perspectives, Volume 9, 1974, pp. 95-109. Also, a copy of the correction to the March 8, 1976 Washington Post article on talc and the summary of the draft Talk Paper anticipated from the FDA was distributed to those present.

C. Lewin Samples

Mr. Sandland summarized the contents of the November, 1975 letter from Henry Davis (FDA) requesting CTFA apply its methodology to several of Dr. Lewin samples provided on a coded basis. The results of the analyses were described by Dr. Rolle.

2. Mt. Sinai Analyses on Old Production Samples

Dr. Petterson gave detailed background on Dr. Langer's work. He stated the objective of the task force should be to develop and collate data that would lead to a presentation before the Miscellaneous External Panel, in order to attempt to have talc placed in Category I. The results of Dr. Pooley's analyses, sponsored by Johnson & Johnson, were summarized.

It was reported that Dr. Langer performed his anaylses on samples purchased in 1973. Mr. Simko described a meeting between himself and Dr. Langer on Tuesday. He estimated the sample of "Cashmere Bouquet" tested was probably a pre-1970 sample. Mr. Mundy (Sterling) reported on his contacts with Dr. Langer and stated the sample Dr. Langer tested was from 1970 production.

3. Recent Production Data

It was agreed by the task force that it would be extremely beneficial if induvidual companies could provide data to the FDA on recent production. Most companies present indicated that they possess such data and would be willing to provide the data. Mr. Messinger (Chesebrough-Pond's) stated he would have to confirm this willingness with his management. It was suggested each company prepare a letter, addressed to Dr. Estrin, with a summary of the data on recent production for their products and a commitment to set-up a subsequent meeting with FDA to discuss this data, in detail, if FDA so desires. This letter should be delivered to Dr. Estrin by Monday, March 15th. Subsequently, a meeting was set-up for that Monday, March 15th, at the CTFA offices, with a meeting at FDA to be held in the afternoon.

4. CTFA Study on Current Production

Advantages and disadvantages of having CTFA contract an independent laboratory to do tests on current production samples was discussed. It was noted that such data would no doubt be useful, not only in discussions with FDA, but also as part of a presentation to the Miscellaneous External Panel and, perhaps, to other panels as well. it was suggested the CTFA methodology be utilized for such a task, but that TEM be used on those samples that have been shown to be positive

CONTINUED ON NEXT PAGE

DCST #	LEWIN #	PRODUCT	TREMOLITE		CHRYSOTILE	
			LEWIN X-RAY	DCST (OM)	LEWIN X-RAY	DCST
1338	72	Lady Ester Face Powder, Rachel	ND	2,800 f/mg.	ND	ND
1339	77	Touch and Glow Face Powder	3	5,600	ND	?
1340	96	Blanchard's Dusting Powder	8	13,000	10	-
1341	97	Born Wild Dusting Powder, Del Labs	12	60,000	15	ND
1342	101	Tai Winds Spray Talc, Avon	15	8,900	ND	ND
1343	102A	Tosca Dusting Powder	10	1,800	7	ND
1344	143	Pin-Zow Talque, Perf. Beauty Prod.	5	400	10	-
1345	144B	Overton's "High Brown" Face Powder	5	ND	?	ND
1346	151	Early American Old Spice Talcum Powder	ND	2,000	ND	-
1347	154	Bismoline Medicated Powder	2	9,000	ND	-
1348	157A	Mavis Imported Talcum	6	ND	8	ND
1349	160	Avon Beauty Dust Refill - Charisma	ND	9,000	trace	ND
1350	163	Pinaud Clubman Talc	10	?	10	-
1351	75	OH! de London Talc, Yardley	ND	-	ND	?
1352	173A	Corsage Dusting Powder	ND	ND	?	?

by CTFA methodology and also be performed on a random basis on other samples. Company representatives were polled at this meeting and previously by Mr. George Lee to determine whether they would be willing to participate in such a study by assuring that current production samples would be provided and that financial support would be given. The results would be made known to the FDA and probably published in some form. The following companies indicated they would be willing to participate:

Avon Products, Inc.
Bristol-Myers Company
Colgate-Palmolive Company
Coty, Inc.
Faberge, Inc.
Johnson & Johnson
Mennen
Sterling

In addition, Chesebrough-Pond's, Mem, and Yardley would probably be interested.

The task force agreed to await the results of the meetings with CTFA before deciding on whether a study on current production should be initiated.

The meeting adjourned in order for a small group to meet with FDA at 2:00 p.m. to discuss the results of CTFA analyses of Dr. Lewin's samples.

Norman F Estrin /asc

Norman F. Estrin, Ph.D.
Vice President - Science

NFE:jj
March 12th, 1976